Clostridium botulinum

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

Aquavit Files Two IND's For Its Botulinum Toxin With FDA

Retrieved on: 
Friday, March 17, 2023

NEW YORK, March 17, 2023 /PRNewswire/ -- Aquavit Holdings, the exclusive licensee of Huons Global's Botulinum Toxin in the USA and Canada, will officially unveil the Aquatox™ program at the Annual American Academy of Dermatology - 2023, the world's largest dermatology conference scheduled from March 17-21, 2023, in New Orleans, LA.

Key Points: 
  • According to The Aesthetic Society and the Global Market Insights, botulinum toxin has been the #1 non-surgical aesthetic procedure since 1999 and is still growing rapidly with only 4 companies with approved botulinum toxin in the US.
  • With a projected CAGR of 7-9%, the global botulinum toxin market in 2026 is expected to be $8.9B.
  • For several years, Aquavit has been investing in its proprietary delivery technologies and related intellectual property for botulinum toxin.
  • We plan to introduce the most innovative botulinum toxin products, uplift and modernize the treatment paradigm" said Sobin Chang, CEO of Aquavit.

Global Botulinum Toxin Market Report 2022: Rising Demand for Non-Invasive and Minimally Invasive Cosmetic Procedures Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022

However, opportunities for its therapeutic applications to expand the botulinum toxin market in the coming years are provided by significant investment in R&D initiatives.

Key Points: 
  • However, opportunities for its therapeutic applications to expand the botulinum toxin market in the coming years are provided by significant investment in R&D initiatives.
  • Top-down and bottom-up approaches were used to estimate and validate the size of the Global Botulinum Toxin Market and to estimate the size of various other dependent submarkets.
  • By type, the market is segmented into botulinum toxin type A, botulinum toxin type B.
  • Based on region the global botulinum toxin market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia

Retrieved on: 
Friday, September 23, 2022

IRVINE, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced positive topline results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the neck.

Key Points: 
  • ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
  • AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.
  • This press release contains forward-looking statements that are based on managements belief and assumptions and on information currently available to management.
  • These and other important factors may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements.

Albertsons Companies Voluntarily Recalls Select Store-Prepared Sandwiches Made With King’s Hawaiian® Pretzel Roll Products

Retrieved on: 
Sunday, August 14, 2022

Albertsons Companies (NYSE: ACI), in cooperation with the voluntary recall of Kings Hawaiian pretzel roll products, is voluntarily recalling 18 store-prepared items made with Kings Hawaiian pretzel rolls.

Key Points: 
  • Albertsons Companies (NYSE: ACI), in cooperation with the voluntary recall of Kings Hawaiian pretzel roll products, is voluntarily recalling 18 store-prepared items made with Kings Hawaiian pretzel rolls.
  • The Kings Hawaiian recall is out of an abundance of caution due to its potential for microbial contamination, including from the organisms Cronobacter sakazakii and Clostridium botulinum.
  • The Kings Hawaiian recall announcement can be found here .
  • The supplier confirmed that no illnesses associated with Kings Hawaiian pretzel bread have been reported, and no pathogens have been found in any Kings Hawaiian products to date.

KING'S HAWAIIAN® ISSUES VOLUNTARY RECALL OF PRETZEL SLIDER BUNS, PRETZEL HAMBURGER BUNS AND PRETZEL BITES DUE TO THE RECALL OF AN INGREDIENT FROM SUPPLIER LYONS MAGNUS

Retrieved on: 
Friday, August 12, 2022

---------------------------------------------------------------------------------

Key Points: 
  • LOS ANGELES, Aug. 12, 2022 /PRNewswire/ -- King's Hawaiian is voluntarily recalling its Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites products out of an abundance of caution following a recall of an ingredient used in the pretzel products from one of its suppliers, Lyons Magnus.
  • While no illnesses associated with King's Hawaiian pretzel bread have been reported, and no pathogens have been found in any King's Hawaiian products to date, the recall is being conducted to ensure consumer safety.
  • Consumers in possession of any King's Hawaiian Pretzel Slider Buns, King's Hawaiian Pretzel Hamburger Buns or King's Hawaiian Pretzel Bites should dispose of the product.
  • King's Hawaiian advises that consumers in possession of any King's Hawaiian Pretzel Slider Buns, King's Hawaiian Pretzel Hamburger Buns or King's Hawaiian Pretzel Bites should dispose of the product.

AEON Biopharma Raises $30 Million from Insiders

Retrieved on: 
Wednesday, August 3, 2022

AEON expects to opportunistically revisit the capital markets in the near future in order to further strengthen its capital position and advance its clinical trials.

Key Points: 
  • AEON expects to opportunistically revisit the capital markets in the near future in order to further strengthen its capital position and advance its clinical trials.
  • AEON licenses ABP-450 from Daewoong Pharmaceutical Co., which provides AEON exclusive development and distribution rights for therapeutic indications in certain territories, including the United States, Canada and the EU, among other international territories.
  • This press release contains forward-looking statements that are based on managements belief and assumptions and on information currently available to management.
  • The forward-looking statements in this press release are made only as of the date hereof.

Glabellar Lines Pipeline Insight Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022

The "Glabellar Lines - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glabellar Lines - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The "Glabellar Lines - Pipeline Insight, 2022" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Glabellar Lines pipeline landscape.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Glabellar Lines R&D.
  • This segment of the report provides insights about the different Glabellar Lines drugs segregated based on the following parameters that define the scope of the report, such as:
    How many companies are developing Glabellar Lines drugs?

AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia

Retrieved on: 
Monday, April 11, 2022

The Phase 2 randomized, double-blind, placebo-controlled study enrolled a total of 59 patients across a total of 25 study sites in the United States.

Key Points: 
  • The Phase 2 randomized, double-blind, placebo-controlled study enrolled a total of 59 patients across a total of 25 study sites in the United States.
  • Patients enrolled into the clinical study are divided evenly across four cohorts, including a low dose (150 units), mid-dose (250 units), high dose (350 units), and placebo.
  • The primary endpoint of the clinical study is to evaluate the safety of a single treatment of ABP-450 over a maximum of 20 weeks.
  • Botulinum toxin is the standard of care for the treatment of cervical dystonia, helping to improve pain, posture, and disability.

Global Botulinum Toxin Market Forecast to 2028 - by Product Type, Application, and End User - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022

The "Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Application, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The botulinum toxin market is expected to reach US$ 8,977.62 million by 2028 from US$ 5,307.71 million in 2021.
  • The factors responsible for the botulinum toxin market's growth are increasing aesthetic procedures and the use of botulinum toxin, and the rising number of non-invasive cosmetic procedures.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global botulinum toxin market.